{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:43:05Z","timestamp":1785300185651,"version":"3.55.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Autoimmune lymphoproliferative syndrome (ALPS) is a rare immune dysregulatory condition, usually presenting in childhood with massive lymphadenopathy, splenomegaly, and an increased incidence of lymphoma. Methods to differentiate between benign ALPS adenopathy and lymphoma are needed. To this end, we evaluated the usefulness of FDG PET.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We prospectively evaluated 76 ALPS\/ALPS-like patients including <jats:italic toggle=\"yes\">F<\/jats:italic>S-7\u2013<jats:italic toggle=\"yes\">a<\/jats:italic>ssociated <jats:italic toggle=\"yes\">s<\/jats:italic>urface antigen (<jats:italic toggle=\"yes\">FAS<\/jats:italic>) germline mutation with (n = 4) and without lymphoma (n = 50), <jats:italic toggle=\"yes\">FAS<\/jats:italic>-somatic (n = 6), ALPS-unknown (n = 6), and others (n = 10) who underwent FDG PET. Uptakes in 14 nodal sites, liver, and spleen were determined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In 76 ALPS patients, FDG PET showed uptake in multiple nodal sites in all but 1 patient. The highest SUVmax values in <jats:italic toggle=\"yes\">FAS<\/jats:italic> mutation without lymphoma, <jats:italic toggle=\"yes\">FAS<\/jats:italic> mutation with lymphoma, <jats:italic toggle=\"yes\">FAS<\/jats:italic> somatic, ALPS-unknown, and other genetic mutations were a median (range) 9.2 (4.3\u201325), 16.2 (10.7\u201337.2), 7.6 (4.6\u201318.1), 11.5 (4.8\u201317.2), and 5.5 (0\u201315.3), respectively. Differences between uptake in the <jats:italic toggle=\"yes\">FAS<\/jats:italic> group with and without lymphoma were statistically significant, but overlapped, making discrimination between individuals with\/without lymphoma impossible. The spleen:liver uptake ratio was greater than 1 in 82% of patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>While statistically significant differences were observed in <jats:italic toggle=\"yes\">FAS<\/jats:italic> mutation ALPS with and without lymphoma, the significant overlap in FDG uptake and visual appearance in many patients prevents discrimination between patients with and without lymphoma. Similar patterns of FDG biodistribution were noted between the various ALPS subgroups.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000002816","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T19:20:08Z","timestamp":1572895208000},"page":"949-955","source":"Crossref","is-referenced-by-count":11,"title":["18F-FDG PET Imaging Features of Patients With Autoimmune Lymphoproliferative Syndrome"],"prefix":"10.1097","volume":"44","author":[{"given":"Jorge A.","family":"Carrasquillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara C.","family":"Chen","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Department of Radiology & Imaging Science, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Price","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie","family":"Whatley","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Department of Radiology & Imaging Science, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilo A.","family":"Avila","sequence":"additional","affiliation":[{"name":"Department of Radiology &Imaging Sciences, Warren Grant Magnuson Clinical Center, National Institutes of Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[{"name":"Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine S.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Koneti","family":"Rao","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V98.1.194","article-title":"The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis","volume":"98","year":"2001","journal-title":"Blood"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1182\/blood-2010-04-280347","article-title":"Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop","volume":"116","year":"2010","journal-title":"Blood"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood-2014-11-567917","article-title":"JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2013-10-535393","article-title":"Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1148\/radiology.212.1.r99jl40257","article-title":"Autoimmune lymphoproliferative syndrome: a syndrome associated with inherited genetic defects that impair lymphocytic apoptosis\u2014CT and US features","volume":"212","year":"1999","journal-title":"Radiology"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.mibio.2004.03.001","article-title":"Positron emission tomography scan findings of autoimmune lymphoproliferative syndrome","volume":"6","year":"2004","journal-title":"Mol Imaging Biol"},{"key":"bib7-20230925","first-page":"99","article-title":"Autoimmune lymphoproliferative syndrome and non-Hodgkin lymphoma: what F-18-fluorodeoxyglucose positron emission tomography\/computed tomography can do in the management of these patients? Suggestions from a case report","volume":"33","year":"2014","journal-title":"Rev Esp Med Nucl E Image Mol"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ajh.20523","article-title":"Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS)","volume":"81","year":"2006","journal-title":"Am J Hematol"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/pbc.24047","article-title":"SUV-measurements and patient-specific corrections in pediatric Hodgkin-lymphoma: is there a benefit for PPV in early response assessment by FDG-PET?","volume":"59","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/cancers7010287","article-title":"FDG-PET response prediction in pediatric Hodgkin's lymphoma: impact of metabolically defined tumor volumes and individualized SUV measurements on the positive predictive value","volume":"7","year":"2015","journal-title":"Cancers (Basel)"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/art.20150","article-title":"A pilot study of the use of 2-F-18-fluoro-2-deoxy-d-glucose-positron emission tomography to assess the distribution of activated lymphocytes in patients with systemic lupus erythematosus","volume":"50","year":"2004","journal-title":"Arthritis Rheum"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/01.aids.0000222070.52996.76","article-title":"Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation","volume":"20","year":"2006","journal-title":"AIDS"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1053\/j.semnuclmed.2013.06.007","article-title":"FDG PET imaging in sarcoidosis","volume":"43","year":"2013","journal-title":"Semin Nucl Med"},{"key":"bib15-20230925","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.2013.50.8044","article-title":"False-positive F-18 fluorodeoxyglucose-avid lymph nodes on positron emission tomography\u2013computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib16-20230925","doi-asserted-by":"crossref","first-page":"E68","DOI":"10.1016\/j.ejrad.2009.07.035","article-title":"F-18-FDG PET and PET\/CT in Burkitt's lymphoma","volume":"75","year":"2010","journal-title":"Eur J Radiol"},{"key":"bib17-20230925","first-page":"565","article-title":"Positron emission tomography in patients with Hodgkin's disease: correlation to histopathologic subtypes","volume":"18","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"bib18-20230925","first-page":"1790","article-title":"Predicting malignancy grade with PET in non-Hodgkin's lymphoma","volume":"36","year":"1995","journal-title":"J Nucl Med"},{"key":"bib19-20230925","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/147323000703500207","article-title":"Standardized uptake values of normal organs on F-18-fluorodeoxyglucose positron emission tomography and computed tomography imaging","volume":"35","year":"2007","journal-title":"J Int Med Res"},{"key":"bib20-20230925","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12149-012-0599-y","article-title":"Dual-time-point F-18-FDG PET\/CT in patients with colorectal cancer: clinical value of early delayed scanning","volume":"26","year":"2012","journal-title":"Ann Nucl Med"},{"key":"bib21-20230925","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/BF02984678","article-title":"Evaluation of delayed F-18-FDG PET in differential diagnosis for malignant soft-tissue tumors","volume":"20","year":"2006","journal-title":"Ann Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T05:00:58Z","timestamp":1695618058000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002816","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,31]]}}}